DF6215-001

A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors

Ouvert à Paris depuis le : 20/11/2024
Public cible : Adult
Phase : Phase I

Description de l'essai

To determine the maximum tolerated dose (MTD) of DF6215.;To determine clinical activity of DF6215.

Url of the trial

Investigateur principal

EMANUELA ROMANO

Médecin

Contacter